Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps

Burger, Herman; van Tol, Hans; Brok, Mariël; A.C. Wiemer, Erik; A. de Bruijn, E.; Guetens, Gunther; De Boeck, Gert; Sparreboom, Alex; Verweij, Jaap; Nooter, Kees

doi:10.4161/cbt.4.7.1826

Public

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps

Published in Cancer Biology & Therapy • Jul 1, 2005

Authors:

Herman Burger

Hans van Tol

Mariël Brok

Abstract

Imatinib mesylate is a selective tyrosine kinase inhibitor that is successfully used in the treatment of Philadelphia-positive chronic and acute leukaemia's, and gastrointestinal stromal tumors. We investigated whether the intended chronic oral administration of imatinib might lead to the induction ...

Subject

Abcg2

Imatinib

Pharmacology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!